Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives

References

• RothJACristianoRJGene therapy for cancer: what have we done and where are we going?J Natl Cancer Inst199789121398978404
   PubMed Web of Science ®Google Scholar
• BrennerMKGottschalkSLeenAMVeraJFIs cancer gene therapy an empty suit?Lancet Oncol20131411e447e45624079872
   PubMed Web of Science ®Google Scholar
• BrownCJLainSVermaCSFershtARLaneDPAwakening guardian angels: drugging the p53 pathwayNat Rev Cancer200991286287319935675
   PubMed Web of Science ®Google Scholar
• BassettEAWangWRastinejadFEl-DeiryWSStructural and functional basis for therapeutic modulation of p53 signalingClin Cancer Res200814206376638618927276
   PubMed Web of Science ®Google Scholar
• MunroAJLainSLaneDPP53 abnormalities and outcomes in colorectal cancer: a systematic reviewBr J Cancer200592343444415668707
   PubMed Web of Science ®Google Scholar
• MartinsCPBrown-SwigartLEvanGIModeling the therapeutic efficacy of p53 restoration in tumorsCell200612771323133417182091
   PubMed Web of Science ®Google Scholar
• LehmannBDPietenpolJATargeting mutant p53 in human tumorsJ Clin Oncol201230293648365022965952
   PubMed Web of Science ®Google Scholar
• WimanKGRestoration of wild-type p53 function in human tumors: strategies for efficient cancer therapyAdv Cancer Res20079732133817419952
   PubMed Web of Science ®Google Scholar
• RothJAGrammerSFTumor suppressor gene therapyMethods Mol Biol200322357759812777752
   PubMedGoogle Scholar
• LaneDPCheokCFLainSp53-based cancer therapyCold Spring Harb Perspect Biol201029a00122220463003
   PubMed Web of Science ®Google Scholar
• ClaymanGLel-NaggarAKRothJAIn vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinomaCancer Res1995551167805018
   PubMed Web of Science ®Google Scholar
• FujiwaraTGrimmEAMukhopadhyayTZhangWWOwen-SchaubLBRothJAInduction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 geneCancer Res1994549228722918162565
   PubMed Web of Science ®Google Scholar
• SpitzFRNguyenDSkibberJMCusackJRothJACristianoRJIn vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancerAnticancer Res1996166B341534229042200
   PubMed Web of Science ®Google Scholar
• KimJHwangESKimJSYouEHLeeSHLeeJHIntraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouseCancer Gene Ther19996217217810195884
   PubMed Web of Science ®Google Scholar
• PagliaroLCKeyhaniALiuBPerrottePWilsonDDinneyCPAdenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatinUrol Oncol200321645646214693272
   PubMed Web of Science ®Google Scholar
• YangCCirielliCCapogrossiMCPassanitiAAdenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cellsCancer Res19955519421042137671222
   PubMed Web of Science ®Google Scholar
• ShimadaHShimizuTOchiaiTPreclinical study of adenoviral p53 gene therapy for esophageal cancerSurg Today200131759760411495154
   PubMed Web of Science ®Google Scholar
• PengZCurrent status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancersHum Gene Ther20051691016102716149900
   PubMed Web of Science ®Google Scholar
• GabrilovichDIINGN 201 (Advexin): adenoviral p53 gene therapy for cancerExpert Opin Biol Ther20066882383216856803
   PubMed Web of Science ®Google Scholar
• WillsKNManevalDCMenzelPDevelopment and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancerHum Gene Ther199459107910887833367
   PubMed Web of Science ®Google Scholar
• HechtJRBedfordRAbbruzzeseJLA phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinomaClin Cancer Res20039255556112576418
   PubMed Web of Science ®Google Scholar
• van BeusechemVWvan den DoelPBGrillJPinedoHMGerritsenWRConditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potencyCancer Res200262216165617112414643
   PubMed Web of Science ®Google Scholar
• WangXSuCCaoHA novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancersMol Cancer Ther2008761598160318566230
   PubMed Web of Science ®Google Scholar
• YamasakiYTazawaHHashimotoYA novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppressionEur J Cancer201248142282229122244827
   PubMed Web of Science ®Google Scholar
• YuWFangHClinical trials with oncolytic adenovirus in ChinaCurr Cancer Drug Targets20077214114817346105
   PubMed Web of Science ®Google Scholar
• FujiwaraTUrataYTanakaNTelomerase-specific oncolytic virotherapy for human cancer with the hTERT promoterCurr Cancer Drug Targets20077219120117346111
   PubMed Web of Science ®Google Scholar
• SteghAHTargeting the p53 signaling pathway in cancer therapy – the promises, challenges and perilsExpert Opin Ther Targets2012161678322239435
   PubMed Web of Science ®Google Scholar
• Gomez-ManzanoCFueyoJKyritsisAPAdenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosisCancer Res19965646946998630997
   PubMed Web of Science ®Google Scholar
• Gomez-ManzanoCFueyoJKyritsisAPCharacterization of p53 and p21 functional interactions in glioma cells en route to apoptosisJ Natl Cancer Inst19978914103610449230885
   PubMedGoogle Scholar
• KöckHHarrisMPAndersonSCAdenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivoInt J Cancer19966768088158824552
   PubMed Web of Science ®Google Scholar
• HaseiJSasakiTTazawaHDual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cellsMol Cancer Ther201312331432523315976
   PubMed Web of Science ®Google Scholar
• ZhangYFZhangBCZhangARCo-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancerOncol Rep20133041989199523933826
   PubMed Web of Science ®Google Scholar
• IdogawaMSasakiYSuzukiHA single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cellsClin Cancer Res200915113725373219458054
   PubMed Web of Science ®Google Scholar
• NishizakiMFujiwaraTTanidaTRecombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effectClin Cancer Res1999551015102310353734
   PubMed Web of Science ®Google Scholar
• WakuTFujiwaraTShaoJContribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancerJ Immunol2000165105884589011067949
   PubMed Web of Science ®Google Scholar
• HanDMHuangZGZhangWEffectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow upZhonghua Yi Xue Za Zhi2003832320292032 Chinese14703409
   PubMedGoogle Scholar
• ZhangSWXiaoSWLiuCQTreatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 casesZhonghua Yi Xue Za Zhi2003832320232028 Chinese14703408
   PubMedGoogle Scholar
• ChenCBPanJJXuLYRecombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II clinical trialZhonghua Yi Xue Za Zhi2003832320332035 Chinese14703410
   PubMedGoogle Scholar
• ZhangSWXiaoSWLiuCQRecombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinomaZhonghua Zhong Liu Za Zhi2005277426428 Chinese16188130
   PubMedGoogle Scholar
• PanJJZhangSWChenCBEffect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinomaJ Clin Oncol200927579980419103729
   PubMed Web of Science ®Google Scholar
• RothJASwisherSGMerrittJAGene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacementSemin Oncol1998253 Suppl 833379704675
   PubMed Web of Science ®Google Scholar
• GuanYSLiuYZouQAdenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-upJ Zhejiang Univ Sci B200910533134019434759
   PubMed Web of Science ®Google Scholar
• NingXSunZWangYDocetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancerCancer Gene Ther201118644444921455255
   PubMed Web of Science ®Google Scholar
• GuanYSLiuYZhouXPLiXHeQSunLp53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinomaGut20055491318131915879012
   PubMed Web of Science ®Google Scholar
• YangZXWangDWangGClinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinomaJ Cancer Res Clin Oncol2010136462563019882171
   PubMed Web of Science ®Google Scholar
• ShimadaHMatsubaraHShiratoriTPhase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinomaCancer Sci200697655456116734736
   PubMed Web of Science ®Google Scholar
• YooGHMoonJLeblancMA phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology GroupArch Otolaryngol Head Neck Surg2009135986987419770418
   PubMedGoogle Scholar
• SchulerMHerrmannRDe GreveJLAdenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyJ Clin Oncol20011961750175811251006
   PubMed Web of Science ®Google Scholar
• BullerRERunnebaumIBKarlanBYA phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerCancer Gene Ther20029755356612082455
   PubMed Web of Science ®Google Scholar
• KuballJWenSFLeissnerJSuccessful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillationJ Clin Oncol200220495796511844817
   PubMed Web of Science ®Google Scholar
• TazawaHKagawaSFujiwaraTAdvances in adenovirus-mediated p53 cancer gene therapyExpert Opin Biol Ther201313111569158324107178
   PubMed Web of Science ®Google Scholar
• DixBRO’CarrollSJMyersCJEdwardsSJBraithwaiteAWEfficient induction of cell death by adenoviruses requires binding of E1B55k and p53Cancer Res200060102666267210825139
   PubMed Web of Science ®Google Scholar
• GoodrumFDOrnellesDAp53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infectionJ Virol19987212947994909811681
   PubMed Web of Science ®Google Scholar
• O’SheaCCJohnsonLBagusBLate viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivityCancer Cell20046661162315607965
   PubMed Web of Science ®Google Scholar
• O’SheaCCSoriaCBagusBMcCormickFHeat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapyCancer Cell200581617416023599
   PubMed Web of Science ®Google Scholar
• HeiseCSampson-JohannesAWilliamsAMcCormickFVon HoffDDKirnDHONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agentsNat Med1997366396459176490
   PubMed Web of Science ®Google Scholar
• ShiinaMLacherMDChristianCKornWMRNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenovirusesCancer Gene Ther2009161181081919407849
   PubMed Web of Science ®Google Scholar
• NemunaitisJGanlyIKhuriFSelective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trialCancer Res200060226359636611103798
   PubMed Web of Science ®Google Scholar
• NemunaitisJKhuriFGanlyIPhase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancerJ Clin Oncol200119228929811208818
   PubMed Web of Science ®Google Scholar
• KhuriFRNemunaitisJGanlyIa controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerNat Med20006887988510932224
   PubMed Web of Science ®Google Scholar
• ReidTRFreemanSPostLMcCormickFSzeDYEffects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorinCancer Gene Ther200512867368115803147
   PubMed Web of Science ®Google Scholar
• ChioccaEAAbbedKMTatterSA phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingMol Ther200410595896615509513
   PubMed Web of Science ®Google Scholar
• MakowerDRozenblitAKaufmanHPhase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studiesClin Cancer Res20039269370212576437
   PubMed Web of Science ®Google Scholar
• GalanisEOkunoSHNascimentoAGPhase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomasGene Ther200512543744515647767
   PubMed Web of Science ®Google Scholar
• LuWZhengSLiXFHuangJJZhengXLiZIntra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trialWorld J Gastroenterol200410243634363815534920
   PubMed Web of Science ®Google Scholar
• XiaZJChangJHZhangLPhase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagusAi Zheng2004231216661670 Chinese15601557
   PubMedGoogle Scholar
• CunBSongXJiaRCombination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle blockCancer Biol Ther2012132778422336909
   PubMed Web of Science ®Google Scholar
• GeoergerBVassalGOpolonPOncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant gliomaCancer Res200464165753575915313916
   PubMed Web of Science ®Google Scholar
• IdemaSLamfersMLvan BeusechemVWAdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapyJ Gene Med20079121046105617966130
   PubMed Web of Science ®Google Scholar
• van BeusechemVWvan den DoelPBGerritsenWRConditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2Mol Cancer Ther2005461013101815956259
   PubMed Web of Science ®Google Scholar
• SongXWangHJiaRCombined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma CellsInt J Mol Sci2012139107361074923109819
   PubMed Web of Science ®Google Scholar
• ChenWWuYLiuWEnhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinomaCancer Lett201130719310321504839
   PubMed Web of Science ®Google Scholar
• KawashimaTKagawaSKobayashiNTelomerase-specific replication-selective virotherapy for human cancerClin Cancer Res2004101 Pt 128529214734481
   PubMed Web of Science ®Google Scholar
• NakajimaOMatsunagaAIchimaruDUrataYFujiwaraTKawakamiKTelomerase-specific virotherapy in an animal model of human head and neck cancerMol Cancer Ther20098117117719139126
   PubMed Web of Science ®Google Scholar
• SasakiTTazawaHHaseiJPreclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomasClin Cancer Res20111771828183821325287
   PubMed Web of Science ®Google Scholar
• HuangPWatanabeMKakuHDirect and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer modelCancer Gene Ther200815531532218274558
   PubMed Web of Science ®Google Scholar
• KojimaTWatanabeYHashimotoYIn vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapyAnn Surg201025161079108620485131
   PubMed Web of Science ®Google Scholar
• LiuDKojimaTOuchiMPreclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancerMol Cancer Ther20098498098719372571
   PubMed Web of Science ®Google Scholar
• TakakuraMNakamuraMKyoSIntraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal disseminationCancer Gene Ther2010171111919662088
   PubMed Web of Science ®Google Scholar